Protalix BioTherapeutics (PLX) Revenue Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.42% |
| Dec 31, 2025 | -14.09% |
| Sep 30, 2025 | 10.59% |
| Jun 30, 2025 | 7.38% |
| Mar 31, 2025 | -14.12% |
| Dec 31, 2024 | 5.44% |
| Sep 30, 2024 | 4.74% |
| Jun 30, 2024 | 1.93% |
| Mar 31, 2024 | -18.52% |
| Dec 31, 2023 | 42.96% |
| Sep 30, 2023 | 73.24% |
| Jun 30, 2023 | 77.23% |
| Mar 31, 2023 | 16.06% |
| Dec 31, 2022 | 36.78% |
| Sep 30, 2022 | 13.51% |
| Jun 30, 2022 | 6.60% |
| Mar 31, 2022 | 57.76% |
| Dec 31, 2021 | 32.66% |
| Sep 30, 2021 | 20.88% |
| Jun 30, 2021 | 29.44% |
| Mar 31, 2021 | 75.55% |
| Sep 30, 2020 | 51.86% |
| Jun 30, 2020 | 52.35% |
| Mar 31, 2020 | 66.49% |
| Mar 31, 2019 | 9.29% |
| Dec 31, 2018 | 17.25% |
| Sep 30, 2018 | -21.92% |
| Jun 30, 2018 | -2.39% |
| Mar 31, 2018 | 5.00% |
| Dec 31, 2017 | 8.96% |
| Sep 30, 2017 | 15.11% |
| Jun 30, 2017 | -24.61% |
| Mar 31, 2017 | -15.68% |
| Dec 31, 2016 | -2.50% |
| Sep 30, 2016 | 32.77% |
| Jun 30, 2016 | 18.28% |
| Mar 31, 2016 | -30.30% |
| Sep 30, 2015 | -15.94% |
| Jun 30, 2015 | 3.21% |